The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity

A. B. Tilden, Andrew Kraft

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We compared the effects of bryostatin 1 (BRYO), a non-tumor-promoting protein kinase C activator, and phorbol myristate acetate (PMA) on various types of lymphocyte cytotoxicity. An 18-h preincubation of lymphocytes with 10-8 M BRYO inhibited natural killer (NK) activity but this inhibition was not statistically significant (p = 0.28). In contrast, NK activity was significantly enhanced by preincubation of lymphocytes with 10-8 M PMA (p = 0.0012). Thus, in 13 experiments, the mean LU/106 was 21 ± 12 for control cultured cells, 16 ± 14 for BRYO cultured cells, and 40 ± 22 for PMA cultured cells as determined in 51Cr-release assays with K562 target cells. Both BRYO and PMA inhibited lymphocyte antibody-dependent cell-mediated cytotoxicity (ADCC) such that, at a 20:1 effector-to-target ratio, control lymphocytes had a mean 49 ± 12% specific 51Cr release of antibody-coated target cells while BRYO and PMA cultured lymphocytes had 12 ± 6 and 8 ± 12%, respectively, in four experiments. The reduction in ADCC was paralleled by a decrease in Fc receptor (CD16) expression as determined by immunofluorescence analysis. We assessed the ability of BRYO and PMA to induce lymphokine-activated killer (LAK) activity by culturing lymphocytes with optimally mitogenic doses of these compounds and testing for cytotoxicity of Daudi target cells. While both BRYO and PMA induced [3H]thymidine uptake, neither induced LAK activity. Furthermore, both compounds inhibited induction of LAK activity by recombinant interleukin-2 (rIL-2) in cocultures. We also analyzed the effect of BRYO and PMA on preactivated LAK effector cells. Lymphocytes were cultured for 3 days with 100 U/ml of rIL-2, aliquoted, and recultured for 18 h with rIL-2 alone and with the addition of 10-8 M BRYO and 10-8 M PMA, and then tested for LAK activity. Both compounds reduced the cytotoxic activity of LAK effector cells.

Original languageEnglish (US)
Pages (from-to)96-104
Number of pages9
JournalJournal of Immunotherapy
Volume10
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Tetradecanoylphorbol Acetate
Lymphocytes
Lymphokines
Interleukin-2
Antibody-Dependent Cell Cytotoxicity
Lymphokine-Activated Killer Cells
Cultured Cells
bryostatin 1
K562 Cells
Fc Receptors
Coculture Techniques
Thymidine
Protein Kinase C
Fluorescent Antibody Technique
Antibodies

Keywords

  • Antibody-dependent cell-mediated cytotoxicity
  • Bryostatin
  • Lymphocyte cytotoxicity
  • Lymphokine-activated killer cells
  • Natural killer cells

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity. / Tilden, A. B.; Kraft, Andrew.

In: Journal of Immunotherapy, Vol. 10, No. 2, 1991, p. 96-104.

Research output: Contribution to journalArticle

@article{6544f937ae0a4e10a37c21eacf22e01e,
title = "The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity",
abstract = "We compared the effects of bryostatin 1 (BRYO), a non-tumor-promoting protein kinase C activator, and phorbol myristate acetate (PMA) on various types of lymphocyte cytotoxicity. An 18-h preincubation of lymphocytes with 10-8 M BRYO inhibited natural killer (NK) activity but this inhibition was not statistically significant (p = 0.28). In contrast, NK activity was significantly enhanced by preincubation of lymphocytes with 10-8 M PMA (p = 0.0012). Thus, in 13 experiments, the mean LU/106 was 21 ± 12 for control cultured cells, 16 ± 14 for BRYO cultured cells, and 40 ± 22 for PMA cultured cells as determined in 51Cr-release assays with K562 target cells. Both BRYO and PMA inhibited lymphocyte antibody-dependent cell-mediated cytotoxicity (ADCC) such that, at a 20:1 effector-to-target ratio, control lymphocytes had a mean 49 ± 12{\%} specific 51Cr release of antibody-coated target cells while BRYO and PMA cultured lymphocytes had 12 ± 6 and 8 ± 12{\%}, respectively, in four experiments. The reduction in ADCC was paralleled by a decrease in Fc receptor (CD16) expression as determined by immunofluorescence analysis. We assessed the ability of BRYO and PMA to induce lymphokine-activated killer (LAK) activity by culturing lymphocytes with optimally mitogenic doses of these compounds and testing for cytotoxicity of Daudi target cells. While both BRYO and PMA induced [3H]thymidine uptake, neither induced LAK activity. Furthermore, both compounds inhibited induction of LAK activity by recombinant interleukin-2 (rIL-2) in cocultures. We also analyzed the effect of BRYO and PMA on preactivated LAK effector cells. Lymphocytes were cultured for 3 days with 100 U/ml of rIL-2, aliquoted, and recultured for 18 h with rIL-2 alone and with the addition of 10-8 M BRYO and 10-8 M PMA, and then tested for LAK activity. Both compounds reduced the cytotoxic activity of LAK effector cells.",
keywords = "Antibody-dependent cell-mediated cytotoxicity, Bryostatin, Lymphocyte cytotoxicity, Lymphokine-activated killer cells, Natural killer cells",
author = "Tilden, {A. B.} and Andrew Kraft",
year = "1991",
language = "English (US)",
volume = "10",
pages = "96--104",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The effect of bryostatin 1 on human lymphocyte-mediated cytotoxicity

AU - Tilden, A. B.

AU - Kraft, Andrew

PY - 1991

Y1 - 1991

N2 - We compared the effects of bryostatin 1 (BRYO), a non-tumor-promoting protein kinase C activator, and phorbol myristate acetate (PMA) on various types of lymphocyte cytotoxicity. An 18-h preincubation of lymphocytes with 10-8 M BRYO inhibited natural killer (NK) activity but this inhibition was not statistically significant (p = 0.28). In contrast, NK activity was significantly enhanced by preincubation of lymphocytes with 10-8 M PMA (p = 0.0012). Thus, in 13 experiments, the mean LU/106 was 21 ± 12 for control cultured cells, 16 ± 14 for BRYO cultured cells, and 40 ± 22 for PMA cultured cells as determined in 51Cr-release assays with K562 target cells. Both BRYO and PMA inhibited lymphocyte antibody-dependent cell-mediated cytotoxicity (ADCC) such that, at a 20:1 effector-to-target ratio, control lymphocytes had a mean 49 ± 12% specific 51Cr release of antibody-coated target cells while BRYO and PMA cultured lymphocytes had 12 ± 6 and 8 ± 12%, respectively, in four experiments. The reduction in ADCC was paralleled by a decrease in Fc receptor (CD16) expression as determined by immunofluorescence analysis. We assessed the ability of BRYO and PMA to induce lymphokine-activated killer (LAK) activity by culturing lymphocytes with optimally mitogenic doses of these compounds and testing for cytotoxicity of Daudi target cells. While both BRYO and PMA induced [3H]thymidine uptake, neither induced LAK activity. Furthermore, both compounds inhibited induction of LAK activity by recombinant interleukin-2 (rIL-2) in cocultures. We also analyzed the effect of BRYO and PMA on preactivated LAK effector cells. Lymphocytes were cultured for 3 days with 100 U/ml of rIL-2, aliquoted, and recultured for 18 h with rIL-2 alone and with the addition of 10-8 M BRYO and 10-8 M PMA, and then tested for LAK activity. Both compounds reduced the cytotoxic activity of LAK effector cells.

AB - We compared the effects of bryostatin 1 (BRYO), a non-tumor-promoting protein kinase C activator, and phorbol myristate acetate (PMA) on various types of lymphocyte cytotoxicity. An 18-h preincubation of lymphocytes with 10-8 M BRYO inhibited natural killer (NK) activity but this inhibition was not statistically significant (p = 0.28). In contrast, NK activity was significantly enhanced by preincubation of lymphocytes with 10-8 M PMA (p = 0.0012). Thus, in 13 experiments, the mean LU/106 was 21 ± 12 for control cultured cells, 16 ± 14 for BRYO cultured cells, and 40 ± 22 for PMA cultured cells as determined in 51Cr-release assays with K562 target cells. Both BRYO and PMA inhibited lymphocyte antibody-dependent cell-mediated cytotoxicity (ADCC) such that, at a 20:1 effector-to-target ratio, control lymphocytes had a mean 49 ± 12% specific 51Cr release of antibody-coated target cells while BRYO and PMA cultured lymphocytes had 12 ± 6 and 8 ± 12%, respectively, in four experiments. The reduction in ADCC was paralleled by a decrease in Fc receptor (CD16) expression as determined by immunofluorescence analysis. We assessed the ability of BRYO and PMA to induce lymphokine-activated killer (LAK) activity by culturing lymphocytes with optimally mitogenic doses of these compounds and testing for cytotoxicity of Daudi target cells. While both BRYO and PMA induced [3H]thymidine uptake, neither induced LAK activity. Furthermore, both compounds inhibited induction of LAK activity by recombinant interleukin-2 (rIL-2) in cocultures. We also analyzed the effect of BRYO and PMA on preactivated LAK effector cells. Lymphocytes were cultured for 3 days with 100 U/ml of rIL-2, aliquoted, and recultured for 18 h with rIL-2 alone and with the addition of 10-8 M BRYO and 10-8 M PMA, and then tested for LAK activity. Both compounds reduced the cytotoxic activity of LAK effector cells.

KW - Antibody-dependent cell-mediated cytotoxicity

KW - Bryostatin

KW - Lymphocyte cytotoxicity

KW - Lymphokine-activated killer cells

KW - Natural killer cells

UR - http://www.scopus.com/inward/record.url?scp=0025767790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025767790&partnerID=8YFLogxK

M3 - Article

C2 - 1828367

AN - SCOPUS:0025767790

VL - 10

SP - 96

EP - 104

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -